Stockwinners Market Radar for August 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment bought 274.4K shares of AvidXchange today

18:25 EDT Rockwell Automation CEO: Underlying demand remains strong - He noted there are a lot of industries that are in the early innings of high investment. Blake Moret is speaking on CNBC.

17:49 EDT Essential Utilities raises quarterly dividend by 7% to 30.7c per share - The dividend is payable September 1, 2023, to all shareholders of record on August 11, 2023.

17:33 EDT Starbucks sees 'significant headroom' for new store growth in U.S. - Says continued to grow and diversify store portflio in Q3. Sees "significant headroom" for new store growth in the U.S. Sees more opportunities in China. Sees "multiple paths" to long-term revenue target. Comments taken from Q3 earnings conference call.

17:30 EDT Erie Indemnity to replace PDC Energy in S&P 400 at open on 8/8 - Chevron (CVX) is acquiring PDC Energy (PDCE) in a deal expected to be completed soon pending final conditions.

17:26 EDT Hess Corp. COO sells $5.06M in common stock - In a regulatory filing, Hess Corp disclosed that its COO Gregory Hill sold 33.4K shares of common stock on July 31 in a total transaction size of $5.06M.

17:24 EDT Signet Jewelers exec sells $1.4M in common stock - In a regulatory filing, Signet Jewelers disclosed that its Chief Consumer Officer Jamie Singleton sold 17.5K shares of common stock on July 31 in a total transaction size of $1.4M.

17:16 EDT WestRock to permanently close paper mill in Tacoma - WestRock announced it will permanently cease operating its paper mill in Tacoma, Washington, and will conclude production by September 30. WestRock is committed to improving its return on invested capital as well as maximizing the performance of its assets. The combination of high operating costs and the need for significant capital investment were the determining factors in the decision to cease operations at the mill. The Tacoma mill produces kraft and white top liner and bleached pulp for a combined annual capacity of 510,000 tons. The Tacoma mill employs approximately 400 people. Employees will receive severance and outplacement assistance in accordance with WestRock policy and labor union agreements.

17:10 EDT NHTSA probes Tesla Model 3 and Model Y for steering wheels issues - On July 28 NHTSA reported opening an investigation on "Loss of steering control"- The Office of Defects Investigation, ODI, is opening a Preliminary Evaluation or PE, on 2023 model year Tesla Model 3 and Model Y vehicles due to reports of inability to steer the vehicle and the loss of power steering, the agency said in a release. ODI has received twelve complaints alleging loss of steering control and power steering in 2023 Tesla Model 3 and Model Y vehicles. Five reports indicate an inability to steer the vehicle. Seven additional reports cite loss of power steering resulting in increased effort to control the vehicle. A PE has been opened to assess the scope, frequency, manufacturing processes, and severity associated with this condition, added the report. Reference Link

17:05 EDT RTX awarded $124.29M Navy contract modification - RTX was awarded a $124.29M cost-plus-incentive-fee, cost-plus-fixed-fee modification to a previously awarded contract. This modification adds scope to procure 42 Maritime Strike Tomahawk Seeker, or MST, suites for the Navy in support of MST Low Rate Production Three, to be installed into Tactical Tomahawk Missiles in the recertification effort. Work is expected to be completed in November 2025. FY23 weapons procurement funds in the amount of $124.29M will be obligated at the time of award, none of which will expire at the end of the current fiscal year. Naval Air Systems Command is the contracting activity.

17:02 EDT Genius Group issued warning letter by NYSE - Genius Group Limited announced it received a Warning Letter from NYSE regarding the manner of disclosures from March 2023 events via Twitter and that the Company violated Section 401 of the Company Guide by failing to disclose material information in compliance with the Company Guide requirements and by providing inconsistent information to the investing public. In accordance with Section 1009(a)(i) of the Company Guide, the Company was issued the Warning Letter.

16:58 EDT Metals Company provides update following ISA Council decisions on mining code - Metals Company provided a corporate update on expected development timeline, production capacity and application costs for its NORI-D Nodule Project following the recent International Seabed Authority (ISA) Council decisions on a roadmap to deliver final rules, regulations and procedures, also known as the Mining Code. The company said, "TMC subsidiary Nauru Ocean Resources Inc. (NORI) intends to submit an application to the ISA for an exploitation contract for NORI Area D following the July 2024 meeting of the ISA. Assuming a one-year review process, NORI expects to be in production in the fourth quarter of 2025. NORI and strategic partner Allseas plan for an increased production capacity for the Project Zero Offshore System, using the Hidden Gem vessel, from an estimated 1.3 million wet tonnes to an estimated 3.0 million wet tonnes per annum, an increase of 130%, including an additional 15-meter-wide collector vehicle, a wider diameter riser pipe, larger compressor spread, and improvements to the system designed to further mitigate its environmental impacts. The Company estimates that it will require $60 to 70 million of additional cash to submit an application for an exploitation contract following the July 2024 meeting of the ISA. TMC had $20M cash on hand and an undrawn $25M unsecured credit facility as of June 30th 2023. Allseas has agreed to extend the maturity date of the $25 million unsecured credit facility provided to the Company through November 30, 2024 on the same terms. In addition, on August 1, 2023, the Company and Allseas entered into an Exclusive Vessel Use Agreement which will give the Company exclusive use of the Hidden Gem in support of the development of the Project Zero Offshore System with 4.15 million common shares to be issued to Allseas as consideration. After listening carefully during the recent ISA meetings, NORI intends to submit an application to the ISA for an exploitation contract for its NORI Area D following the July 2024 session, by which time the ISA would have concluded three additional ISA Council sessions while continuing with intersessional working groups. Following feedback received from the ISA's Legal and Technical Commission (LTC), NORI will further add to its growing body of environmental data by conducting a new post-collection test campaign this year, a campaign which was originally slated to be part of NORI's Environmental Management & Monitoring Plan (EMMP) post application, which the Company believes will strengthen the quality of NORI's Environmental Impact Statement (EIS) and EMMP by providing additional information on the environmental regeneration of the collection test area. Based on observations during the 2022 post-collection test monitoring campaign as well as information shared by other contractors, NORI expects that the results of this additional campaign will further enhance the quality of its application. Consistent with NORI's rights under the United Nations Convention on the Law of the Sea (UNCLOS), and the 1994 Agreement relating to the Implementation of Part XI of UNCLOS (the Agreement), NORI reserves its right to submit an application for a plan of work for exploitation, which will be included as part of the application for an exploitation contract, prior to the ISA's provisional adoption and approval of the Mining Code, the possibility of which was recognized in the ISA Council decisions ISBA/28/C/24 and ISBA/28/C/25, and to have that application considered and provisionally approved pursuant to Section 1, Paragraph 15 of the Annex to the Agreement. Assuming a one-year review process for an application, NORI expects to be in production in the fourth quarter of 2025."

16:58 EDT Ternium sees Q3 EBITDA down from Q2 - The company states: "Excluding the impact of the consolidation of Usiminas on Ternium's financial results, Ternium expects third quarter EBITDA to decrease compared to the second quarter, with higher shipments partially offset by a lower EBITDA margin that will result from a decrease in international prices and slightly higher cost per ton. In Mexico, the company anticipates higher sequential shipments in the third quarter, driven by continued strength in the automotive and white-goods industrial sectors. In addition, Mexico's commercial market remains stable, with no significant accumulation of inventories in the commercial value chain. In Argentina, Ternium expects shipments in the third quarter to remain at the same level as in the second quarter. However, the company anticipates that high inflation, constraints to imports of raw materials, the significantly unstable macroeconomic environment and upcoming election-related uncertainty would negatively impact domestic steel market activity and demand in the second half of 2023."

16:52 EDT W&T Offshore lowers FY23 CapEx view to $50M-$70M from $90M-$110M - Addressing updated guidance for the balance of 2023, Tracy Krohn, CEO, commented, "We have always believed that the key to long-term sustainability is to prioritize free cash flow generation. In the first half of 2023, we have seen commodity price weakness, with much lower natural gas prices and soft oil prices. As a result, we decided to proactively reduce our current year capital budget and delay a significant portion of our drilling capital investments until 2024. We believe that the lower pricing scenario enhances acquisition opportunities, and we have a strong cash position and balance sheet to act quickly should we see the right acquisition opportunity arise. We feel that patience is important as we are looking for strategic value and free cash flow generation potential in all acquisition opportunities that we are currently evaluating. Assuming no acquisitions for the remainder of the year, we are reducing our capital expenditure plans for 2023 from a range of $90M-$110M to $50M-$70M, and are focused on maintaining cash which will result in a related deferral of production. We will continue to invest in workovers and recompletions this year to help mitigate natural declines in production. We have successfully built W&T over the past 40 years with a proven acquisition strategy and believe the market will afford us several opportunities in the near term. One of the most attractive attributes of our asset base is our ability to adjust our drilling plans without losing drilling opportunities since our leases are largely held by existing production."

16:46 EDT Mosaic provides market outlook - "Grain and oilseed markets are expected to remain tight through 2023 and likely beyond. The disruption to Ukraine's agricultural production caused by war, coupled with reduced fertilization and sub-optimal weather in major growing regions threaten global agricultural production. This suggests that global stocks-to-use ratios for grains and oilseeds will remain under pressure. Agriculture fundamentals are driving crop prices higher and leading to favorable grower economics. In North America, a strong spring application season depleted fertilizer inventories, which are now being replenished. In Brazil, an attractive fertilizer-to-soybean barter ratio suggests a recovery in fertilizer shipments in 2023. For both potash and phosphates, supply constraints remain. In potash, we expect 2023 shipments from Belarus will be down 5-6 million tonnes from pre-sanction export rates, while North American potash exports are limited by constraints at western ports. In phosphates, China's exports are expected to see only a modest recovery from the lows in 2022 but remain well below shipments seen in 2021. In both phosphates and potash, the fundamental tightness in global markets is expected to persist through 2023 and likely beyond."

16:45 EDT Steris sees FY24 EPS $8.60-$8.80, consensus $8.68 - As announced on June 20, STERIS signed a definitive agreement to purchase the surgical instrumentation, for $540M. All applicable antitrust waiting periods for the Transaction have expired and STERIS now anticipates that the Transaction will close in early August. The Company is updating fiscal 2024 outlook to reflect the Transaction. For fiscal 2024, the company now expects as reported revenue to increase 9-10%, an increase from previous expectations of 7-8%, solely reflecting the Transaction. Expectations for constant currency organic revenue growth are unchanged at 6-7%. Adjusted earnings per diluted share are anticipated to be in the range of $8.60 to $8.80, increased from prior expectations of $8.55 to $8.75, reflec ting $0.05 contribution from the acquired assets. Free cash flow for fiscal 2024 is now anticipated to be $685 million, a decrease from prior expectations of $700 million, reflecting working capital funding requirements for the Transaction.

16:40 EDT Columbia Sportswear falls 5% to $73.34 after FY23 guidance cut

16:36 EDT Best Buy names Ulta Beauty CEO Kimbell to board - Best Buy (BBY) has appointed David C. Kimbell, a specialty retail executive, to its Board of Directors, effective immediately. Kimbell is the Chief Executive Officer of Ulta Beauty (ULTA), the largest specialty beauty retailer in the U.S., and has held the role since June 2021. He also sits on its Board of Directors. Since joining Ulta Beauty in 2014, he has served in leadership roles including President and Chief Merchandising and Marketing Officer. "Dave's leadership experience in specialty retail and service is an incredible asset to our organization, and I am thrilled to welcome him to the Board," said Corie Barry, Chief Executive Officer at Best Buy. "His proven record of leading and transforming numerous top brands and retailers, while focusing on what's best for their employees and communities, will be invaluable as we continue to create the future of retail for evolving consumers."

16:31 EDT Invitation Homes names Allison Mullis chief HR officer - Invitation Homes announced that Allison Mullis will join the Company as Executive Vice President and Chief Human Resources Officer on August 7. "At Invitation Homes, advancing our role as the nation's premier home leasing company means we are continually working to ensure that our greatest asset - our best-in-class team - is rewarded with a strong culture, competitive compensation and benefits, and exceptional learning opportunities," said Chief Executive Officer Dallas Tanner. "We are excited to welcome Allison to the Invitation Homes team and look forward to her leadership on maintaining and building on our exceptional workplace and our overall business."

16:30 EDT Electronic Arts falls 3% to $131.50 after Q1 report

16:29 EDT KKR opens new office in Los Angeles - KKR announced the expansion of its West Coast operations with the opening of a new office in Los Angeles. Located in Century City, the space will initially support the firm's real estate, private equity, private wealth and institutional client relationship teams. Ryan Stork, Partner and Chief Operating Officer of KKR, said, "We have had a significant presence on the West Coast for four decades and we are pleased to grow our footprint in Southern California with the opening of a new office in Century City. We deliberately selected a location that provides flexibility for further expansion to support the needs of our business."

16:23 EDT FirstEnergy affirms FY23 operating guiudance

16:21 EDT Pioneer Natural sees Q3 oil production 367-377 MBOPD - Third quarter 2023 oil production is forecasted to average between 367 to 377 MBOPD and total production is expected to average between 705 to 725 MBOEPD. Production costs are expected to average $10.50 per BOE to $12.00 per BOE. DD&A expense is expected to average $10.50 per BOE to $12.00 per BOE. Total exploration and abandonment expense is forecasted to be $10 million to $20 million. G&A expense is expected to be $80 million to $90 million. Interest expense is expected to be $40 million to $45 million. Other expense is forecasted to be $20 million to $40 million. The cash flow impact related to purchases and sales of oil and gas, including firm transportation, is expected to be a loss of $20 million to $60 million, based on forward oil price estimates for the quarter. The Company's effective income tax rate is expected to be between 22% to 27%, with the current income tax provision for the quarter expected to be $175 million to $250 million, representing pro rata estimated federal and state taxes based on forecasted 2023 taxable income. The Company expects its cash tax rate for the full-year 2023 to approximate a mid-to-high teens percentage of book income.

16:14 EDT Flowserve, Velan extend outside date of arrangement agreement - Flowserve and Velan announced that they have extended the outside date (the "Outside Date") of the arrangement agreement made as of February 9, 2023, among Velan, 14714750 Canada Inc. ("Purchaser") and Flowserve US Inc., as amended by the first amendment to the arrangement agreement dated March 27, 2023 (the "Arrangement Agreement"). In accordance with the definition of Outside Date in the Arrangement Agreement, given that the Regulatory Approvals (as such term is defined in the Arrangement Agreement) have not all been obtained at this time, Velan and Purchaser have given written notices to each other that they each wish to extend the Outside Date for an additional 30 days to September 7, 2023.

16:13 EDT SolarEdge down 12% after Q3 guidance misses estimates - SolarEdge shares are down $29.45, or 12%, to $210.02 in after-hours trading.

16:10 EDT Gulfport raises 2023 production guidance to 1,035 MMcfe - 1,055 MMcfe per day - This is an increase of 1% to 3% based upon the company's previously issued guidance range. The company reduced per unit operating costs to $1.16 - $1.24 per Mcfe, an improvement of approximately 4% based upon the midpoint of the company's previously issued guidance range.

16:08 EDT Starbucks to discuss FY23 financial targets during call - The company will discuss fiscal year 2023 financial targets during its Q3 earnings conference call starting today at 5:00 p.m. Eastern Time, the company stated.

16:07 EDT Pinterest reports Q2 global MAUs up 8% to 465M

16:07 EDT Starbucks CEO says 'strong' Q3 points to 'all-around momentum in the business' - Starbucks CEO Laxman Narasimhan said: "Our strong third quarter results point to all-around momentum in the business, and reflect the significant progress we are making against our Reinvention Plan. Our results were also amplified by the distinctive competitive advantages that set us apart in the market. Starbucks is an iconic, durable brand and I am confident in the multiple paths available for the company to drive significant growth and margin improvement, which position us well to create outsized long-term shareholder value."

16:02 EDT Forte Biosciences announces $25M financing and R&D update - Forte Biosciences announced key R&D updates for FB-102 and the closing of financing to support the advancement of FB-102. Forte's wholly owned antibody, FB-102, targets CD-122, a subunit of the IL-2 and IL-15 receptor and mediates NK and CD8+ T cells, which have been implicated in a variety of autoimmune and immune related diseases. FB-102 has demonstrated potentially best in class activity including in validated models of GvHD with superiority to standard of care both as a single agent and in combination with standard of care. In a validated preclinical model of aggressive acute GvHD using transplanted human donor PBMCs, FB-102 reported 90% survival versus 0% survival on vehicle control and compared to 60% survival on ruxolitinib. In combination with ruxolitinib, the only FDA-approved treatment for acute GvHD, FB-102 reported 90% survival compared to 0% survival on vehicle control and 30% survival for ruxolitinib alone with extended duration of dosing compared to the single agent study. Additionally, in a mouse model of chronic GvHD conducted by Forte, anti-CD-122 treatment has shown superior activity compared to placebo or ruxolitinib. CEO Paul Wagner stated: "FB-102 had demonstrated potentially best in class activity including in graft versus host disease, an indication for which there is a very high unmet medical need and potentially abbreviated clinical development pathway. We plan to advance FB-102 into the clinic in 2024. Beyond GvHD, based on extensive proof of concept data, we believe FB-102 has considerable opportunity in a variety of indications with large markets. Our financing by top-tier institutional investors highlights the meaningful potential for FB-102. We are deeply appreciative of the support from preeminent institutional biotechnology investors including Alger, BVF Partners, Farallon Capital Management, Perceptive Advisors and Tybourne Capital Management."

15:05 EDT Luminar announces addition of former SpaceX, GoPro executives - Luminar (LAZR) announced two new executives have decided to join, including Emily Shanklin, who most recently served as "the senior most marketing executive at SpaceX." The company also announced that Kevin Hinge, who most recently served as the chief supply chain officer at GoPro (GPRO), is joining Luminar to "consolidate and scale its manufacturing, supply chain, and quality operations."

14:38 EDT Nucor CFO Laxton sells $2.2M in company shares - The CFO of Nucor, Stephen Laxton, disclosed the sale of 12,765 shares of company stock at $171.46 per share on July 31, for a total transaction amount of $2,188,677.

14:04 EDT Zillow and Redfin team to help buyers and home builders connect - Zillow Group's (Z, ZG) new-construction listings will soon be automatically syndicated to Redfin (RDFN), connecting home builders with motivated buyers on both platforms. The strategic partnership will dramatically expand the reach of home builder listings on Zillow and allow Redfin customers to explore a broader range of new-construction homes for sale, creating a seamless home-buying experience. The new partnership comes at a time when new construction is gaining prominence among buyers. In June 2023, new single-family home sales were up 23.8% from a year ago. This is partly because the inventory of existing homes is dwindling and consumers are shifting to new construction to find a home that meets their needs. Zillow's latest market report shows there were 28% fewer new listings added to the market this June compared to last year. A Redfin analysis found that in the first half of 2023, one-third of single-family homes available for buyers to choose from were new construction, a record-high share...As part of the rollout, Redfin will launch new features to help buyers discover new-construction communities and connect with home builders, powered by Zillow's Community pages. These pages highlight important community amenities, featuring photos, videos, community maps and amenity details, which is incredibly important to new-construction buyers. According to Zillow's 2023 New Construction Consumer Housing Trends Report, 53% of new-construction buyers greatly value shared amenities such as clubhouses and fitness centers, compared to only 24% of existing home buyers...Upon the launch of the partnership, Redfin will source non-MLS new-construction listings exclusively from Zillow. New-construction listings available through an MLS will still be discoverable on Redfin.

13:01 EDT Marsh McLennan Agency acquires Graham Company, terms not disclosed - Marsh McLennan Agency announced the acquisition of Philadelphia, Pennsylvania-based Graham Company, a leading risk management consultancy and one of the top independent insurance and employee benefits brokers in the United States. Terms of the acquisition were not disclosed. Founded in 1960, Graham Company specializes in providing business insurance, employee benefits, and surety brokerage services to companies in a range of high-risk industries, including construction, real estate, manufacturing and distribution, health and human services, and professional services. All 215 Graham employees, including Ken Ewell, President & Chief Operating Officer, and Bill Graham, Chairman, will join Marsh McLennan Agency and continue to work from the company's offices in Philadelphia and New York City.

12:32 EDT Interactive Brokers reports July DARTs up 9% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for July. Brokerage highlights for the month included: 1.991 million Daily Average Revenue Trades, 9% higher than prior year and 2% higher than prior month. Ending client equity of $386.2 B, 23% higher than prior year and 6% higher than prior month. Ending client margin loan balances of $43.2B, 2% higher than prior year and 3% higher than prior month. Ending client credit balances of $98.8B, including $3.3B in insured bank deposit sweeps, 5% higher than prior year and about even with prior month. 2.33 million client accounts, 19% higher than prior year and 2% higher than prior month. 193 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.01 including exchange, clearing and regulatory fees.

12:27 EDT 3M completes sale of assets from dental local anesthetic portfolio for $70M - 3M announced it has completed the sale of certain assets from its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A., a provider of services for the pharmaceutical industry, for a purchase price of $70M, subject to closing and other adjustments.These local anesthetic products, sold primarily in Europe and Asia, include products sold under the Ubistesin, Xylestesin and Mepivastesin brands as well as related syringe and needle products. These were formerly a part of the dental materials business in 3M's Oral Care Solutions Division. As part of ongoing strategic portfolio management, 3M decided to exit these products and prioritize investments that leverage its Health Care business' core Oral Care technologies. 3M has retained ownership of its Seefeld facility and operations, which support 3M's Oral Care business. These local anesthetic products had annual sales in 2022 of approximately $30M and the impact of its ongoing operations were not material to 3M's financial results. 3M expects to record a gain in the third quarter of 2023 related to this business's divestiture which it will reflect as an adjustment in arriving at results, adjusted for special items.

12:01 EDT Smart for Life announces 1-for-3 reverse stock split - Smart for Life will effect a 1-for-3 reverse stock split of its common stock, par value $0.0001 per share and its authorized stock, that will become effective on August 2, 2023. Smart for Life's common stock will continue to trade on The Nasdaq Capital Market under the symbol "SMFL" and will begin trading on a split-adjusted basis when the market opens on August 2, 2023. The new CUSIP number for the Common Stock following the reverse split will be 83204U400. Among other considerations, the reverse split is intended to maintain the Company's compliance with the minimum bid price requirement for maintaining the listing of its common stock on the NASDAQ Capital Market and to make the bid price more attractive to investors. In addition, the split is part of a larger strategic plan to support future acquisition financings, including multiple accretive acquisitions currently and prospectively in the Company's pipeline.

12:00 EDT North European Oil Royalty Trust falls -20.0% - North European Oil Royalty Trust is down -20.0%, or -$3.03 to $12.15.

12:00 EDT Emergent BioSolutions rises 16.8% - Emergent BioSolutions is up 16.8%, or $1.16 to $8.04.

12:00 EDT Tupperware Brands rises 28.3% - Tupperware Brands is up 28.3%, or $1.21 to $5.48.

11:56 EDT Honda reports July U.S. sales up 56.9% to 111,762 units - Honda and Acura brands "leverage new products to top 111,000 units in July despite continued industry logistics and supply challenges," the company reports. American Honda reports July total sales of 111,762 units, up 56.9% from the same month of last year. Reference Link

11:36 EDT Beacon completes acquisition of All American Vinyl Siding Supply - Beacon has completed the acquisition of All American Vinyl Siding Supply of Tupelo, MS. Year to date in 2023, Beacon has expanded its branch footprint through the completion of six acquisitions and the opening of 14 new greenfield locations.

11:02 EDT Airbus Ventures announces investment in Impulse Space - Airbus Ventures announces its investment in Impulse Space, Inc. - a company engaged in the development of in-space transportation services for the inner solar system - which has raised $45M in its oversubscribed Series A funding round. The round is led by RTX Ventures, with participation from Founders Fund, Lux Capital, Airbus Ventures, Space Capital, and others.

11:01 EDT TransMedics to acquire Summit Aviation; financial terms not disclosed - TransMedics Group announced that it has signed a definitive agreement to acquire Summit Aviation, a premier U.S. charter flight operator. The deal is expected to close in the third quarter of 2023, subject to the satisfaction of closing conditions. Upon closing, Ben Walton, Founder of Summit, will join TransMedics as VP of Aviation Services. "We are thrilled to partner with one of the leading teams in the air charter industry as we establish TransMedics Aviation as the first national provider of air logistics dedicated to organ transplantation in the U.S.," said Waleed Hassanein, MD, President and CEO.

10:34 EDT JetBlue: 'Handful' of A321neo jets affected by engine issue

10:18 EDT JetBlue: New York margins still lagging 2019 levels by high single digits

10:13 EDT Sysco made 'significant headway' in improving supply chain efficiencies - Say making progress on reducing expenses. Expects to make further operating expense progress in 2024. Says business is positioned for success in 2024. Says upgraded digital shopping platform during Q2. Says will continue to improve digital tools over time. Says Recipe for Growth is working. Comments taken from Q4 earnings conference call.

10:10 EDT JetBlue CEO 'not satisfied' with change to FY23 EPS guidance

10:07 EDT JetBlue: Decision to terminate NEA to result in near-term drag on margins - Sees 20c-25c EPS headwind to FY outlook, with biggest impact in Q4.

10:06 EDT Roper Technologies CEO Neil Hunn joins Deere board of directors - Deere & Company (DE) announced the election of Neil Hunn to the company's board of directors. He currently serves as President and CEO of Roper Technologies (ROP). "We are pleased to welcome a business leader of Neil's stature to the Deere board," said John C. May, chairman and CEO.

10:01 EDT Interactive Brokers launches fractional shares trading for Canadian stocks, ETFs - Interactive Brokers announced the launch of fractional shares trading for Canadian stocks and ETFs. Clients of Interactive Brokers can now buy and sell fractional shares of all stocks and ETFs listed on the Toronto Stock Exchange and on CBOE Canada, plus eligible U.S. and European stocks and ETFs. To trade eligible Canadian fractional shares, clients can use a cash quantity order that lets clients place orders in a specific cash amount. Fractional shares will automatically be bought or sold if the cash amount does not line up with a whole number of shares.

10:00 EDT Insperity falls -16.4% - Insperity is down -16.4%, or -$19.25 to $98.40.

10:00 EDT Mativ rises 12.1% - Mativ is up 12.1%, or $1.90 to $17.64.

10:00 EDT Tupperware Brands rises 17.6% - Tupperware Brands is up 17.6%, or 75c to $5.02.

09:57 EDT Third Point sees 'mild recession' for U.S. economy - In its Q2 letter to investors dated July 31, Daniel Loeb's Third Point said it sees continued favorable economic conditions driven by declining inflation, which should eventually lead to less hawkish monetary policy. The fund also sees potential for the Federal Reserve to begin an easing cycle around the time American consumers "begin to run low on cash, which should make for a mild recession." Since consumers and businesses would be going into any economic slowdown with healthy balance sheets, the risk of a credit dislocation is minimal in the coming year, also reducing the risk of a severe recession, Third Point wrote.

09:55 EDT Third Point 'sized up' investment in 'clear AI winner' Microsoft - In its Q2 letter to investors dated July 31, Daniel Loeb's Third Point stated: "We have sized up our investments in certain cloud software businesses including Microsoft, a clear AI winner as a result of its rapidly growing Azure cloud business, upside from applying AI features to its core Office products, investment in Open AI, and ability to provide AI services to other companies." The firm added: While LLM-enabled products are in their infancy, exciting early use cases are emerging across several major application categories including productivity software, content creation software, customer relationship management software, and enterprise resource planning software. Companies will monetize this by offering higher-priced AI-enabled versions of existing products, resulting in accelerating ARPU and faster revenue growth, as Microsoft has recently demonstrated with its plan to sell its Office Copilot software at a roughly 2x price increase over the existing non-AI version."

09:50 EDT ContextLogic trading resumes

09:47 EDT Aaron's falls -14.8% - Aaron's is down -14.8%, or -$2.34 to $13.48.

09:47 EDT Electriq Power falls -16.0% - Electriq Power is down -16.0%, or -$1.04 to $5.45.

09:47 EDT Tupperware Brands rises 13.6% - Tupperware Brands is up 13.6%, or 58c to $4.85.

09:37 EDT Fifth Wall Acquisition Corp III trading resumes

09:35 EDT Evolve Transition Infrastructure LP trading resumes

09:32 EDT Fifth Wall Acquisition Corp III trading halted, volatility trading pause

09:31 EDT ContextLogic lays off 34% of workforce, or 255 employees - ContextLogic said its board approved a plan to reduce the company's workforce by approximately 255 employees, representing about 34% of its current global workforce. This includes approximately 160 employees in the United States, representing about 41% of the company's domestic workforce and approximately 95 non-U.S. employees, representing about 26% of the company's international workforce. The workforce reduction plan is intended to "refocus the Company's operations to support its ongoing business prioritization efforts, better align resources, and improve operational efficiencies." ContextLogic estimates it will incur non-recurring charges of approximately $8.7M related to WARN Act compliance, severance payments to affected employees globally, and other personnel reduction costs in connection with the plan. The company expects that the majority of these charges will be incurred in Q3. The company expects to realize run-rate savings of approximately $43M to $46M on an annualized basis starting in Q4.

09:29 EDT Caterpillar 'feels good' about quality of backlog - Says still seeing "healthy demand." Being "proactive" with dealers. Says still some supply chain constraints, but seeing improvement. Says sales, price increases to users will be positive in 2H23. Does not expect same margin improvement in 2H23 as seen in prior four quarters.

09:20 EDT ContextLogic trading halted, news pending

09:18 EDT Brilliant Earth releases The Capture Collection - Brilliant Earth Group announced the launch of two new planet first lab grown diamond collections. The assortment includes lab diamonds produced with carbon, captured before entering the atmosphere, and manufactured with clean energy. The diamonds are created from atmospheric carbon, using unique sequestration technology to pull the CO2 from the air and transform it, benefiting the environment throughout the process. It also includes lab diamonds that are grown, cut and polished with 100% renewable energy.

09:15 EDT Tenable Holdings announces new enhancements to its OT Security - Tenable announced new enhancements to Tenable OT Security, helping customers strengthen the security of their OT environments through the broadest and deepest visibility, granularity, management and control of IT/OT and IoT assets on the market. Tenable OT Security now features increased visibility of Building Management Systems. Marty Edwards, Deputy CTO for OT/IoT at Tenable, said, "All too often, OT, IoT and BMS devices are overlooked, yet in today's converged environments, security teams need a simple, unified view of their overall risk. Tenable OT Security addresses this, enhancing visibility to reduce the attack surface."

09:13 EDT Clearmind Medicine files patent application with USPTO for treating dyskinesia - Clearmind Medicine has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office, as part of its overarching strategy to further strengthen its robust IP portfolio. The patent application refers to the psychedelic molecule 3-Methylmethcathinone as a potential treatment for Dyskinesia thus expanding Clearmind's IP portfolio for innovative molecules, new indications and treatments. "Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio. Since our inception, 24 months ago, we have consistently extended our reach beyond MEAI, to additional second-generation psychedelic compounds," said Clearmind's Chief Executive Officer, Dr. Adi Zuloff-Shani. "There are several forms of Dyskinesia and various different causes including substance and alcohol withdrawal, and long-term use of medications, such as in Parkinson's disease and other mental health disorders. Regardless of form or cause, it severely impairs patients' daily functioning. We believe our targeted treatments have the potential to bring relief to this underserved population."

09:12 EDT Finacity facilitates renewal, investor transition to MUFG - Finacity announces that it has facilitated the renewal and investor transition to Mitsubishi UFJ Financial Group (MUFG) of the $200 million Accounts Receivables Securitization Program for Cushman & Wakefield (CWK), a leading global real estate services firm headquartered in Chicago, IL.

09:10 EDT Churchill Capital Corp VII trading resumes

09:09 EDT MidCoast Council deploys Check Point Infinity - Check Point announced that MidCoast Council in New South Wales has deployed Check Point Infinity, a cyber security architecture built to prevent sophisticated Fifth Generation attacks across networks, cloud deployments, endpoints, mobile and IoT devices.

09:08 EDT Catalent names Lisa Evoli Chief Human Resources Officer - Catalent announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately. Ms. Evoli joins Catalent from Integra Lifesciences, a global medical technology company based in Princeton, New Jersey.

09:07 EDT U.S. Physical Therapy acquires 70% stake in five clinic practice for $2.1M - U.S. Physical Therapy announced an acquisition of a physical therapy practice with five clinics. USPH acquired a 70% equity interest in the practice for a purchase price of $2.1M, with the current practice owners retaining a 30% equity interest. The business currently generates approximately $2.4M in annual revenues.

09:06 EDT SkyHawk Security introduces Shift Left CDR technology - Skyhawk Security is re-inventing its approach with the introduction of Shift Left CDR technology, an industry first. Skyhawk's Shift Left CDR innovation moves the threat detection process further to the left, even before the events happening at the perimeter, making the crown jewels themselves the starting point. Using generative AI and machine learning, the patent-pending Shift Left CDR technology makes a contextual analysis of the infrastructure and determines potential paths hackers could take to them. Armed with this predictive information, Skyhawk's CDR platform can more effectively identify potentially serious threats, thus prioritizing incidents that can risk the organization's crown jewels, alerting on those events that matter much earlier and reducing the noise created by false alarms.

09:05 EDT Churchill Capital Corp VII to take CorpAcq public in deal valued at $1.58B - CorpAcq Holdings and Churchill Capital Corp VII, a special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination. The transaction values CorpAcq at a pro forma enterprise value of approximately $1.58B and is expected to provide CorpAcq with up to $592M in the cash held in Churchill VII's trust account. Upon closing of the transaction, the combined company will operate as CorpAcq and intends to list on the New York Stock Exchange. Based in Altrincham, England and founded in 2006, CorpAcq defines itself as the "preferred buyer" for founder-led small and medium-sized enterprises. CorpAcq founder and chairman Simon Orange will continue to lead the company, along with Chief Executive Officer David Martin. Upon completion of the transaction, CorpAcq expects to have up to approximately $199M in cash on its balance sheet, of which $129M is coming from transaction proceeds. Assuming no redemptions, existing CorpAcq shareholders will receive up to approximately $257M in cash as part of the transaction and are expected to own approximately 46% of the company post-close. The transaction has been approved by the boards of CorpAcq and Churchill VII, is expected to close in late 2023 or early 2024.

09:04 EDT TeleVox, Oracle Cloud enter strategic partnership - With its new strategic partnership with Oracle Cloud Infrastructure, TeleVox's patient engagement solutions are now easily accessible by even more healthcare customers, adding to TeleVox's reputation as the industry-leading provider of omnichannel digital patient engagement. "Together with Oracle, we will strengthen our ongoing commitment to improving communication between patients and providers at the digital front door and across the patient journey," said Vik Krishnan, President of TeleVox. "TeleVox already independently serves hundreds of Oracle Health customers, but with OCI as TeleVox's hyperscaler platform, we will enhance our ability to offer patient engagement solutions at mass scale." TeleVox is a part of West Technology Group, LLC controlled by affiliates of certain funds managed by Apollo Global Management.

09:02 EDT Trust Stamp announces 31% increase in its financial services customer base - Trust Stamp provides an update regarding the adoption of its low-code Orchestration Platform, which streamlines delivery and implementation of the Company's proven technologies. Since Trust Stamp's previous announcement in January 2023 that 22 financial institutions with over $50B in assets and over 850 branches were at various stages of implementing its Orchestration Layer, an additional 7 institutions, including the U.S. arm of a global institution with over 1,500 branches and assets in excess of $1.5T, have commenced the process of implementing the Orchestration Layer.

08:53 EDT Champions Oncology enters multi-year agreement wit BioVolume - Champions Oncology announced an agreement to adopt BioVolume's leading 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume's cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions consistent focus on delivering the highest quality data and scientific excellence, the adoption of BioVolume technology will enable achievement of greater accuracy, reduced variability, and the generation of reliable insights to advance oncology drug development programs across different therapeutic modalities. BioVolume is advancing global preclinical oncology by providing greater study accuracy and helping strengthen drug filings for clinical trials with a digital record of preclinical efficacy. Specifically, BioVolume detects, segments, and measures subcutaneous tumor growth in rodents. By providing traceable imaging for each volume measurement alongside the additional capture of tumor height, it ensures greater reproducibility of study data and offers a statistically significant reduction in variability compared to calipers which rely on manual measurement. In silico modelling of BioVolume data demonstrates that reducing variability can decrease the chance of missing a therapeutic effect by a factor of seven in comparison to existing caliper-based processes.

08:52 EDT Marriott to launch new reservations, loyalty platforms, says CEO - The company says it will be launching new reservations, loyalty and property management platforms over the next several years.

08:50 EDT Univar Solutions completes transaction with Apollo Funds - Univar Solutions (UNVR) and Apollo (APO) announced that Apollo Funds have completed the previously announced acquisition of the company, which includes a minority investment from a wholly owned subsidiary of the Abu Dhabi Investment Authority. The company will continue to operate under the Univar Solutions name and brand and maintain its global presence. Pursuant to the terms of the transaction, an affiliate of the Apollo Funds acquired all of the outstanding shares of Univar Solutions stock. Shareholders are entitled to receive $36.15 in cash for each share of Univar Solutions common stock owned. As a result of the transaction completion, Univar Solutions' common stock no longer trades on the New York Stock Exchange.

08:47 EDT Marriott expects to return $4.1B-$4.5B to shareholders in 2023

08:47 EDT Steel Dynamics restarts hot mill at Sinton Texas Flat Roll Steel Mill - Steel Dynamics announced the restart on July 28 of the hot mill at its Sinton Texas Flat Roll Steel Mill after an unplanned outage began on July 1. The outage related to caster shear equipment issues, which the team has successfully addressed. The company continued to operate Sinton's cold mill and downstream value-added flat rolled steel coating lines during the outage.

08:46 EDT SoundThinking's Data for Good program to be implemented by Fort Lauderdale PD - SoundThinking announced that the Fort Lauderdale Police Department, PD, has agreed to implement SoundThinking's Data for Good program. The program's official launch on August 1st coincides with National Night Out, an annual community-building campaign that promotes police-community partnerships.

08:45 EDT Marriott: U.S. economy could have a soft landing -

08:44 EDT Caterpillar expects FY23 ME&T free cash flow 'around the top' of $4B-$8B range

08:42 EDT ABVC BioPharma signs term sheet to earn licensing fees, royalties - ABVC Biopharma announced the signing of a legally binding term sheet with a prominent Chinese pharmaceutical company, Xinnovation Therapeutics Co., Ltd that, subject to definitive agreements, is for the exclusive licensing of ABV-1504 for Major Depressive Disorder and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China. Under this landmark agreement, Xinnovation Therapeutics Co., Ltd will hold exclusive rights to develop, manufacture, market, and distribute our innovative drugs for MDD and ADHD in the Chinese market and shall bear the costs for clinical trials and product registration in China. The licensing deal carries a possible aggregate income of $20 million for ABVC. The term sheet outlines the key terms and conditions of the licensing agreement. The final agreement, expected to be formally signed within one year, will specify the precise licensing terms, including the schedule for milestone payments and other financial arrangements. As per the term sheet, ABVC expects to receive royalty payments ranging from 5% to 12% based on the projected annual net sales of licensed drugs in China, which we believe would bring ABVC's revenue ~$50 million annually and ~$1 billion during the patent life of these products, if we achieve the expected amount of sales. The final agreement is subject to the satisfaction of closing conditions, and the transaction will not occur if they are not satisfied or waived within one year.

08:42 EDT Caterpillar sees further weakness in China

08:41 EDT MamaMancini's changes name to Mama's Creations - MamaMancini's Holdings announced a corporate name change to Mama's Creations, Inc. - reflecting its evolution into a national deli prepared foods platform company. In conjunction with the name change, the Company's common shares will continue to trade on The Nasdaq Capital Market under the new ticker symbol "MAMA" beginning tomorrow, August 2, 2023. No action is required by the Company's shareholders as a result of these changes. To reflect the changes, Mama's Creations has launched a new corporate and investor relations website at www.mamascreations.com. The new website aligns Mama's Creations with public company best practices by introducing a unified interface to learn more about the Mama's Creations family of brands, as well as an enhanced investor relations section featuring a streamlined design, improved functionality and intuitive access to essential investor information.

08:39 EDT Intelligent Bio secures 8 new customers with combined workforce of 10,000 - Intelligent Bio Solutions announced it has secured 8 new customers across various locations throughout Australia, which collectively employ over 10,000 individuals, within just two months of launching its Intelligent Fingerprinting Drug Screening System in Australia. "Our rapidly expanding customer footprint across the region is a testament to our innovative technology and the quality and value of our drug screening solution," said Harry Simeonidis, President and Chief Executive Officer of Intelligent Bio Solutions. "We remain focused on advancing this growth and delivering a convenient and dignified alternative that continues to meet the screening needs of businesses across Australia."

08:38 EDT Iteris awarded contracts for smart mobility in Midwest, no terms - Iteris announced that it has been awarded contracts for smart mobility, safety and sustainability projects by two agencies in the Midwest: Indianapolis Metropolitan Planning Organization and Mid-America Regional Council . These projects represent expanded Midwest operations due to continued demand in the region. Under the terms of the first contract with IMPO, Iteris will update the Indianapolis ITS Architecture to reflect current ITS systems and services provided in the Indianapolis region. The project will include stakeholder engagement to identify the current and planned elements and provide updated architecture content. In addition, Iteris will provide an analysis of regional transportation operations and the potential of a Transportation Systems Management and Operations Program. Under the second contract with MARC, Iteris will provide traffic engineering and signal timing services for the Operation Green Light Program, an effort to improve the operation of traffic signals on major routes throughout 27 agencies in the Kansas City area. This two-year agreement involves identifying innovative traffic signal retiming techniques to improve safety and mobility, reducing stops and traffic congestion, and increasing sustainability. Through minimizing delays and stops on key corridors, Operation Green Light will help reduce emissions that contribute to ground-level ozone, which is the Kansas City area's main air pollutant.

08:36 EDT Astronics says combined orders in backlog represent $20M in revenue from OEMs - Astronics announced that it has accepted purchase orders to provide certain electrical power distribution, conversion, and vehicle charge control capabilities from ten eVTOL aircraft OEMs who are developing electrical aircraft for emerging air mobility missions. These orders include Astronics' previously announced program win to provide its enhanced CorePower electrical power distribution system for the Lilium Jet. The combined orders represent approximately $20M in sales over the period to certification and consist of hardware deliveries along with engineering support to achieve aircraft certification. Once certified, Astronics expects these initial sales to result in long-term production contracts. Jon Neal, President of Astronics Advanced Electronic Systems, said "Over the last few years Astronics has expanded its CorePower product offerings to include a suite of high power electrical power management capabilities that are critical to the safe and efficient operation of small, electric aircraft. Our OEM customers have chosen Astronics because of our breadth of products, our technical expertise, and our commitment to supporting them through certification. Astronics is excited to be part of the electrification of aircraft moving towards more sustainable and cleaner modes of transportation."

08:36 EDT ANA announces carbon dioxide removal purchase from 1PointFive - All Nippon Airways, ANA, announced a CDR credit purchase agreement with Occidental Petroleum's 1PointFive, a carbon capture, utilization and sequestration company based in Houston, Texas. ANA becomes the first airline in the world to sign a purchase agreement with 1PointFive, further strengthening its commitment to achieve carbon neutrality by 2050. This purchase aligns with ANA's broader climate transition strategy, which focuses on reducing emissions through operational and infrastructure improvements and Sustainable Aviation Fuel, as well as removing residual emissions through Direct Air Capture.

08:34 EDT Hesai collaborating with Nvidia in autonomous car integration - Hesai (HSAI) announced a collaboration with Nvidia (NVDA) to integrate Hesai's cutting-edge lidar sensors within the Nvidia Drive and Nvidia Omniverse ecosystems. By combining Hesai's industry-leading expertise in lidar sensors with Nvidia's AI, simulation, and software development platforms, the collaboration will unlock new possibilities for the autonomous driving industry. Nvidia DriveWorks is the foundation for autonomous vehicle software development and a solution for creating and deploying autonomous driving applications. Nvidia Drive Sim is a simulation platform that aims to enable developers to test and validate autonomous driving systems in a physically based virtual environment. Hesai's AT128 is an automotive-grade, ultra-high resolution long-range lidar. The Nvidia Drive and Omniverse collaboration expands on Hesai's participation in the Nvidia partner ecosystem, which has been ongoing since 2019.

08:33 EDT Qualigen announces U.S. FDA IND clearance to initiate Phase 1 trial of QN-302 - Qualigen Therapeutics announces that the U.S. Food and Drug Administration has cleared the Company's IND application for QN-302, a potential best-in-class small molecule G-Quadruplex-selective transcription inhibitor. Based on this clearance, the Company plans to initiate the Phase 1 clinical trial in the second half of 2023 and will enroll patients with advanced or metastatic solid tumors. Michael Poirier, Qualigen's Chairman and CEO, commented, "This is a pivotal milestone for our therapeutics pipeline as it transitions us into a clinical-stage company. The IND clearance for QN-302 brings us closer to our objective of developing best in class treatments that can potentially provide new therapeutic options for patients with advanced or metastatic solid tumors. Our clinical team has worked diligently to prepare for this milestone and is now dedicated to start enrolling patients, anticipated to take place in the second half of 2023."

08:28 EDT Mace Security announces extension of bank credit agreement - Mace Security has extended the maturity date of its bank credit agreement to September 30, 2023 from July 31, 2023. In conjunction with the extension, the credit facility will be reduced to $1.25 million from $1.5 million on and after September 1, 2023, and the interest rate was changed to SOFR plus 6% from SOFR plus 4%. Under the extension the Company is required to reimburse the bank's legal, accounting, consulting, and audit fees incurred in connection with the extension of approximately $20,000. The extension fee of $50,000 will be waived if the bank line of credit is repaid in full by the Company on or before September 30, 2023. The agreement provides the Company additional time to close a replacement credit facility, which it is diligently pursuing.

08:26 EDT Liberty Resources announces launch of new Investor Relations website - Liberty Resources Acquisition announced the successful launch of a new investor relations website. The investor relations website features an easy to navigate format and streamlined access to essential investor information, including recent company press releases, sector information and more. As previously announced, Liberty entered into a definitive business combination agreement effective December 15, 2022 that will result in Liberty becoming a wholly owned subsidiary of Liberty Onshore Energy B.V.

08:25 EDT Ocean Biomedical shares details of its Lung Cancer Program - Ocean Biomedical is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 is a master regulator that inhibits antitumor immune responses. Ocean Biomedical's lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. These programs suppress primary and metastatic tumor growth in multiple animal models and have potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical's programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer. "On World Lung Cancer Day, we are proud to be part of the global effort to cure this terrible disease," commented Ocean Biomedical's CEO, Elizabeth Ng. We are working on the systematic steps needed to progress the anti-CHi3L1 antibodies into the clinic to potentially become impactful new cancer therapeutics."

08:23 EDT MaxCyte signs strategic platform license with Prime MedicinePrime Medicine - MaxCyte (MXCT) announced the signing of a strategic partnership with Prime Medicine (PRME). Under the terms of the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual license fees and program-related revenue. "We are pleased to partner with Prime Medicine and support their breakthrough gene editing technology," said Doug Doerfler, President and CEO of MaxCyte. "The company's innovative vision and transformative scientific approach are clearly reshaping how genetic diseases are studied and ultimately will be treated."

08:21 EDT Potbelly announces strategic growth in Florida - Potbelly Corporation announced that it has nearly 50 locations in various stages of development throughout the state of Florida. Over the past year, the brand has finalized multi-unit agreements with five franchise groups to develop 46 shops in six critical regions: Tampa, Orlando, Fort Myers, Broward County, Gainesville and Panama City. "Florida as a whole holds immense promise for Potbelly, and we are strategically expanding in the Sunshine State to reach our potential," said Lynette McKee, senior vice president of franchising at Potbelly. "With experienced franchise groups ready to showcase the Potbelly difference, I have no doubt that we will continue to grow our loyal customer base as we bring our brand to new regions across the state."

08:20 EDT Mangoceuticals engages RedLime Solutions - Mangoceuticals announces that it has engaged RedLime Solutions. Redlime has worked with major companies such as Pepsi, Nokia, Pizza Hut, and AT&T having developed various custom software solutions for them and their partners. "Bringing the RedLime team into the equation is a significant step toward engaging more customers, elevating the MangoRx customer experience, reducing the friction around expanding our product offerings, and laying a foundation for accelerating growth through new strategies, features, and verticals," remarked Jacob Cohen. Mangoceuticals, Inc.'s Co-Founder and CEO. "This will add eight top-tier dedicated software developers to our already talented team, unleashing a new dimension to our growth outlook as we shift into a new gear focused on commercialization of new, innovative men's health and wellness products and financial performance."

08:19 EDT scPharmaceuticals announces positive Type C feedback from FDA on FUROSCIX - scPharmaceuticals announced that the Company has received positive Type C meeting feedback from the US Food and Drug Administration, FDA, regarding the potential expansion of the FUROSCIX indication to allow for use in New York Heart Association, NYHA, Class IV heart failure patients. FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure. "We are very pleased with the outcome of our recent Type C meeting with the FDA, and believe this paves the way for potential expansion of the FUROSCIX indication to allow for use in NYHA Class IV patients," stated John Tucker, Chief Executive Officer of scPharmaceuticals. "We estimate that as many as 10% of all heart failure patients are Class IV, and a meaningful percentage of these - as many as 40% - may benefit from FUROSCIX. To that end, we plan to file for Class IV indication expansion by the end of this year." The Company also announced the issuance of U.S. patents covering concentrated formulations of furosemide. This enables the possibility of developing additional furosemide formulations for subcutaneous administration that will provide clinicians with additional dosing flexibility.

08:18 EDT Mobiquity Technologies, Optical Near ME rollout joint marketing program - Mobiquity Technologies and Optical Near ME announce the rollout of their joint marketing program. Since announcing the strategic alliance on July 18, 2023, ten optical care enterprises in the U.S. have embraced Mobiquity's Audience Resolution Services, a set of innovative tools that empower businesses with robust data visualization capabilities. The technology offers insights into audiences visiting their digital platforms, enabling a better understanding of their customers, and tailoring their message to drive higher conversions of current visitors and attract new ones. Dean Julia, CEO of Mobiquity Technologies, stated, "This collaboration will empower eyecare businesses with the tools they need to succeed in this rapidly evolving landscape. Most of these businesses could not afford to navigate this terrain independently, considering the technological cost, as well as the required expertise. We offer them the opportunity to focus on their eye care services while we manage the rest."

08:15 EDT Grifols accelerates healthcare innovation with Google Cloud's AI, analytics - Grifols (GRFS) has announced a collaboration agreement with Google Cloud (GOOG;GOOGL) to harness its powerful technologies such as artificial intelligence to greatly accelerate the development of new Grifols biopharma medicines. AI featuring large language models will be applied across the drug-development life cycle, including identifying potential therapeutic candidates and managing clinical trial programs, to significantly reduce the time required to bring novel treatments to market. "Grifols will reinvent biopharma medicine as we know it so we can bring more treatments to more patients in more parts of the world," said Albert Grifols Coma-Cros, Grifols Chief Scientific Innovation Officer. "Turbocharging our extensive knowledge of biopharma and plasma science with the most advanced data technologies from Google Cloud will benefit patients and society."

08:13 EDT Worksport announces early start of production in New Western N.Y. factory - Worksport announced the commencement of production in its new 220,000 square-foot West Seneca, NY, facility, a week ahead of its scheduled launch. Steven Rossi, Worksport CEO, expressed his excitement, "It's a proud moment for us. Not only are we beginning ahead of schedule, but our state-of-the-art $4million custom manufacturing line is ready to roll, backed by a team of experts. Our readiness today stands testament to our resilience, adaptability, and commitment." Rossi continued, "Meeting the expected market demand for our innovative hard- and soft-folding light truck tonneau covers just became swifter. This early kickoff marks the first step towards our vision for the SOLIS solar cover, which will be made possible once our redesigned COR battery system enters the market."

08:12 EDT Verde Clean Fuels in carbon capture deal for renewable gasoline plant in CA - Verde Clean Fuels (VGAS) announced a Carbon Dioxide Management Agreement CDMA between Verde and Carbon TerraVault , a carbon management partnership focused on carbon capture and sequestration development formed between Carbon TerraVault, a subsidiary of California Resources Corporation (CRC), and Brookfield Renewable (BEP). Under the terms of the agreement, Verde will construct a new renewable gasoline production facility at CRC's existing Net Zero Industrial Park in Kern County, California. CTV JV initially plans to sequester a minimum of 100,000 metric tons per year of carbon dioxide from Verde's facility at the CTV I carbon storage vault. This emissions avoidance is the equivalent of taking nearly 22,000 passenger vehicles off the road. This new facility is expected to produce approximately 21,000 gallons per day of renewable gasoline from biomass and other agricultural waste feedstock to help support the further decarbonization of California's economy and its transportation sector.

08:11 EDT Udemy announces Badging offering, Integrated Skills Framework - Udemy announced availability of its new Badging offering. The capabilities were introduced as part of an Integrated Skills Framework methodology designed to help organizations make sense of the complex skills landscape so that they can future-proof their workforce and keep pace with innovation. Leveraging Udemy solutions, organizations will be able to assess their current technical skills landscape, identify critical gaps, and supply employees with an effective way to acquire and validate skills mastery. In service of this, Udemy has also partnered with 1EdTech, to bring the Open Badges standard to its platform, enabling employees to focus on course content that aligns with the most in-demand technical certifications and verifiable badges like AWS, Azure, CompTIA and more. Udemy's new Badging offering along with the Integrated Skills Framework, serve as a powerful guide to help organizations effectively address three critical phases of skill-building: discovery, preparation and demonstration.

08:05 EDT Bragg Gaming launches new content with FanDuel in Michigan, Connecticut - Bragg Gaming (BRAG) announced that it has launched its new proprietary content and Remote Games Server, or RGS, technology with FanDuel (PDYPY) in Michigan and Connecticut. FanDuel's players in Michigan and Connecticut now have access to an initial selection of games from Bragg Studios brands including Atomic Slot Lab, Indigo Magic and Spin Games - as well as selected exclusive Powered by Bragg titles from third-party developers. The launch of Bragg's new exclusive content with FanDuel in Michigan and Connecticut represents an extension of an existing collaboration between the two online gaming companies in North America, with Bragg's Spin Games content already live with the operator in New Jersey and Ontario. In addition, the company began rolling out its newest Bragg Studios content with FanDuel in Ontario in June.

08:04 EDT The CW Network and Hearst Television expand and extend affiliation partnership - The CW Network announced that it has expanded and extended its network affiliation agreement with Hearst Television. With the comprehensive multi-year agreement, Hearst will continue carrying The CW's entertainment and sports programming in six markets across the country, and commencing on September 1, will launch The CW on Hearst's KQCA-TV, a new CW affiliate in Sacramento, California. Financial terms of the agreement were not disclosed. "Hearst has been an important partner for The CW throughout the years and we are extremely pleased to be launching a new CW affiliate in Sacramento," said Dennis Miller, President of The CW Network. "KQCA-TV is already home to LIV Golf in Sacramento, and this agreement will ensure that viewers there won't miss a moment of our other highly-rated sports and entertainment programming, including ACC college football and basketball, and INSIDE THE NFL, both of which premiere this fall."

08:02 EDT Tyra Biosciences announces FDA Orphan Drug Designation for TYRA-300 - Tyra Biosciences announced that the U.S. FDA has granted Orphan Drug Designation to its lead precision medicine program, TYRA-300, for the treatment of achondroplasia. Achondroplasia is the most common form of dwarfism with limited therapeutic options. People living with achondroplasia may experience severe skeletal complications including cranial and spinal stenosis, hydrocephalus and sleep apnea. A specific mutation in FGFR3 causes over 97% of achondroplasia. TYRA-300 is an oral FGFR3 selective inhibitor whose design may have a meaningful impact on achondroplasia and other skeletal dysplasias.

07:59 EDT Calian Group completes acquisition of Hawaii Pacific Teleport - Calian Group has completed the acquisition of US-based Hawaii Pacific Teleport for up to CAD$62M.The acquisition marks Calian's further move into the US following its acquisition of Computex in March 2022. It will also expand the Calian Advanced Technologies portfolio further into global markets. HPT has operated for over 20 years as an independent teleport and continues to be the first choice for Asia Pacific satellite communications service providers. Leveraging its service locations across the Hawaiian Islands and Guam, HPT provides secure, contiguous connectivity throughout the Asia Pacific region from its strategically located US based locations.

07:57 EDT CureVac doses first patient in Phase 2 study of COVID-19 vaccine candidates - CureVac announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK. A first data read-out of the study is expected early in the first half of 2024. The Phase 2 study will evaluate safety, reactogenicity and immune responses of single booster doses of two modified mRNA COVID-19 vaccine candidates. The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant. In line with the current standard of care, the bivalent candidate, CV0701, encodes the spike protein of the omicron BA.4-5 variant as well as the original SARS-CoV-2 strain. The study is active-controlled, featuring a licensed bivalent COVID-19 comparator vaccine. Enrollment started at clinical sites in Australia. The study is expected to enroll approximately 415 healthy adult participants. As previously reported, in CureVac and GSK's ongoing Phase 1 trial of CV0501, a monovalent, modified mRNA COVID-19 vaccine candidate encoding the spike protein of the omicron BA.1 variant, preliminary data showed a favorable tolerability profile. Preliminary immunogenicity data indicated relevant ratios of post-boost to pre-boost neutralizing antibody titers beginning at the lowest tested dose. The CureVac-GSK COVID-19 collaboration was first announced in February 2021 and focuses on the development and manufacturing of potential vaccines against SARS-CoV-2 variants to address current healthcare needs and help prepare against future SARS-CoV-2 outbreaks.

07:54 EDT Merck reports Q2 Keytruda sales grew 19% to $6.3B

07:53 EDT Ivanhoe Electric provides update on drilling programs underway - Ivanhoe Electric Executive Chairman, Robert Friedland and President and Chief Executive Officer, Taylor Melvin are pleased to provide an update on current exploration activities at the Company's U.S. electric metals exploration projects. Ivanhoe Electric's experienced exploration teams are operating eight diamond drill rigs at its projects: Two drill rigs are exploring the Tintic Copper-Gold-Silver Project, located 60 miles south of Salt Lake City, Utah. Two drill rigs are exploring the Hog Heaven Copper-Gold-Silver Project, located 50 miles southwest of Kalispell, Montana. One drill rig is exploring the Lincoln Copper-Gold-Silver Project, located in southern Utah. Three drill rigs are actively supporting technical work at the Santa Cruz Copper Project, located west of Casa Grande, Arizona. In addition to exploration drilling, Ivanhoe Electric recently completed a three-dimensional induced polarization geophysical survey, using our proprietary Typhoon technology, over 25 square kilometers at the White Hill Copper Project in western Nevada. Mr. Friedland commented: "The amount of exploration activity underway at our US projects is impressive. Our team of talented and experienced geologists and geophysics specialists have been hard at work this summer and will remain so well into the fall. We look forward to providing additional updates on our progress as we advance our important exploration activities in the United States. It is exciting to see our experienced exploration teams simultaneously advancing multiple projects in the United States. We are combining the talents of our teams with our proprietary Typhoon geophysical surveying technology to search for the next generation of electric metals supply. In addition to work on our robust exploration portfolio, we are finalizing the Initial Assessment for our Santa Cruz Copper Project in Arizona. We continue to expect that study to be complete by the end of Q3 2023."

07:51 EDT Jacobs to design highway infrastructure for Brent Spence Bridge Corridor Project - Jacobs was selected as part of the Walsh Kokosing Joint Venture Design-Build Team to deliver critical infrastructure as part of the Brent Spence Bridge Corridor Project. The BSBC will deliver approximately eight miles of improved Interstates 71 and 75 through Kentucky and Ohio, including the addition of a new companion bridge. The Ohio Department of Transportation and Kentucky Transportation Cabinet estimate the contract value at $3.1B. Jacobs will also serve as the independent companion bridge engineer, performing design checks of the new river crossing.

07:48 EDT Sanuwave Health signs distribution agreement with Pacific Medical - SANUWAVE Health announced a long term partnership with Pacific Medical, Inc. to distribute and sell the UltraMIST line of wound care products in the Western United States. Pacific Medical is an award-winning leader in medical equipment sales and support with over 215 salaried sales representatives, 75 of which are dedicated to the wound care space, and has been integral to the growth of numerous innovative medical devices and technologies. "We are excited to be entering into business with such an established and well-respected firm with a history of helping to define new markets and innovations," said SANUWAVE EVP of Sales Tim Hendricks. "This is how we will take the next steps toward establishing our leadership in the next generation wound care space and expand the footprint of our "Energy First" treatment modalities."

07:47 EDT Magna announces start of production of modular eDecoupling unit for BEVS - Magna announced the start of production of a first-to-market, modular eDecoupling unit to support multiple battery electric vehicle programs for a German premium OEM. "Our new and innovative modular eDecoupling unit aligns perfectly with OEMs' in-house manufacturing strategies for electric drive systems," said Diba Ilunga, President Magna Powertrain. "Due to the compact design of the unit, we've successfully minimized added package space and weight in both axial and radial direction, which has helped ensure that it can be scalable for use across electric and hybrid vehicles from B segment up to SUVs and LCVs."

07:46 EDT Harpoon Therapeutics appoints Haibo Wang as SVP, business - Harpoon Therapeutics announced the appointment of Haibo Wang as Senior Vice President of Business Development. Wang most recently served as Vice President of Business Development at Hummingbird Bioscience where he was responsible for the company's end-to-end business development activities.

07:44 EDT MediWound announces commercial launch of NexoBrid in Japan - MediWound announced that its strategic partner, Kaken Pharmaceutical, launched NexoBrid in Japan for the treatment of deep partial thickness and full thickness burns in adults and pediatric patients. Kaken Pharmaceutical, a top ranked Japanese pharmaceutical company, has the exclusive marketing and distribution rights for NexoBrid in Japan. NexoBrid is indicated for the removal of eschar in deep partial and full thickness thermal burns. "As one of the top healthcare markets worldwide, Japan holds special strategic importance. Over 6,000 patients are treated for severe burns in Japan every year, with a majority of these patients undergoing eschar removal as a critical first step. NexoBrid can now be a non-surgical treatment option for these patients," stated Ofer Gonen, Chief Executive Officer of MediWound. "We are proud to have Kaken Pharmaceutical, a trusted and valuable partner, leading the commercialization of NexoBrid in this key market. Kaken Pharmaceutical is a major drug manufacturer in Japan with a unique core marketing competency for both drugs and medical devices, which is critical in promoting a product like NexoBrid."

07:43 EDT Sharecare announces five new customer activation, management solutions - Sharecare announced five new solutions designed to engage, educate, and activate patients to better understand the conditions impacting their lives and take meaningful actions towards improving their health and well-being. With extensive digital capabilities and a zero party-database of over 100 million, Sharecare's new customer activation and management solutions for life sciences companies build on emerging consumer trends to reach the right people at the right time with contextually relevant, actionable information they want and can trust. Available to reserve now for fourth quarter 2023 and 2024 campaigns, the newest customer activation and management solutions from Sharecare include: Population Perspective - Complementing Sharecare's robust catalog of award-winning health equity content, this solution informs, inspires, and connects minority populations with resources to help them find culturally competent, condition-specific care as well as actionable advice. Life Unscripted - Featuring relatable and candid first-person advice from real patients living with a specific condition, this solution showcases a variety of content to engage and support individuals on their personal health journeys, including animated videos; curated lists of "go-to" resources; day-in-the-life video diaries; and interactive cheat sheets with actionable tips. Oncology Roadmap - Created to support patients and their caregivers, this solution helps people navigate the cancer treatment journey by delivering clinician perspectives on managing care; conversation guides to support discussions with healthcare providers and loved ones; information about the types of specialists that may comprise one's care team; and direct access to medically vetted, condition-specific articles. Myth-information - Designed to drive and elevate productive provider-patient discussions, this tool utilizes an interactive and easy-to-understand quiz format to help individuals assess their knowledge about their condition, while simultaneously dispelling common myths and misinformation. Point-of-Care Network - Sharecare's partners can enhance their campaigns and strategic planning through a new targeted point-of-care solution available across 1,100 dedicated on-site testing and diagnostic facilities - which reach over 1.3 million patients per month and engage over 160 million patients annually, many of whom are managing a specific condition.

07:42 EDT Occidental Petroleum, ADNOC to evaluate carbon management projects - Occidental and ADNOC announced that they will evaluate investment opportunities in Direct Air Capture facilities and carbon dioxide sequestration hubs in the United States and the United Arab Emirates as a pathway toward the development of carbon management platforms to accelerate the net-zero goals of both companies. The strategic collaboration between global energy leaders Occidental and ADNOC demonstrates how the companies can work together on the potential deployment of carbon capture, utilization and sequestration technology at scale in the United States and the Middle East and to help hard-to-abate industries achieve their net-zero targets through the purchase of carbon dioxide removal credits alongside emissions reduction programs. Under the terms of the Memorandum of Understanding, ADNOC may evaluate participation in DAC plants and CO2 sequestration hubs under development in the United States by Occidental subsidiary, 1PointFive. Occidental and ADNOC and may also evaluate jointly developing one or more UAE-located CO2 sequestration hubs and consider commencing feasibility and pre-front-end engineering and design studies for a 1 million tonne-per-year DAC plant, which together would provide emissions reduction solutions for carbon-intensive industrial emitters and other hard-to-abate sectors within the UAE, including aviation and maritime operations.

07:41 EDT StateHouse revises debt obligations - StateHouse Holdings has entered into an agreement with Pelorus Equity Group as Administrative Agent and Collateral Agent to the Credit and Guaranty Agreement, dated as of December 21, 2020, as amended, to extend the repayment date of the Series A Loan Agreement to February 10, 2027 and increase the amount of the Series A Loan. Pursuant to the terms of the Debt Modification Agreement, Pelorus is providing an incremental term loan of $7.521 million, to bring the total principal amount of the Series A Loan Agreement to $15.0 million. The Company will use the funds for repayment of the Series A indebtedness, servicing the Company's other debts to Pelorus, including any interest owing thereon, and payment of property taxes. Pursuant to the terms of the Debt Modification Agreement, the Pelorus Loan will bear an interest rate of one month Secured Overnight Financing Rate. plus 12.5%, with a SOFR floor of 4.5%. The Pelorus Loan remains subject to certain debt service ratio requirements, interest reserves, certain cross-corporate guarantees and defaults, subordination agreements and intercreditor agreements, along with a general corporate guaranty from the Company. In accordance with the terms of the Debt Modification Agreement the debt service coverage ratio measurement date will be extended to July 2024. As consideration for providing the Pelorus Loan, the Company has agreed to grant to Pelorus 136,258,279 warrants of the Company, amounting to 40% of the Pelorus Loan. The Pelorus Warrants are exercisable, for a period of three years, into common shares of the Company. Pelorus will have the right to a cashless exercise of the Pelorus Warrants. The exercise price of the Pelorus Warrants is adjustable on a weighted-average dilution basis. The distribution of assets or dividends will only be provided to Pelorus upon exercise of the Pelorus Warrants. Pelorus will be prohibited from exercising the Pelorus Warrants if, upon exercise, Pelorus would beneficially own greater than 9.99% of the outstanding common shares of the Company. The Pelorus Warrants cannot be transferred to another party without the consent of the Company, unless the transfer is to an affiliate of Pelorus or the Company is found to be in default of the Pelorus Loan. The holder of the Pelorus Warrants has also been granted a put option, so long as the Pelorus Warrants have not been exercised, to sell the Pelorus Warrants to the Company at a thirty percent discount to their then current exercise price, exercisable via written notice to the Company at least fifteen days prior to the prepayment or maturity date of the Pelorus Loan. If the holder of the Pelorus Warrants fails to exercise this put option during such time period, the put option is deemed void ab initio.

07:37 EDT SunPower to become exclusive lease and PPA provider for ADT Solar - SunPower (SPWR) announced that ADT Solar, a division of ADT ( ADT), has entered into an agreement in principle with SunPower Financial to become the exclusive lease and PPA provider for ADT Solar customers. Through this arrangement, ADT Solar expects to begin offering customers a lease option for the first time. SunPower Financial plans to act as the exclusive lessor for ADT Solar customers that choose to finance with a lease or power purchase agreement - PPA -. ADT Solar intends to make products offered by SunPower Financial available to its customers this year. In the future, the two companies expect to explore opportunities to collaborate on additional streamlined solar and smart home services for homeowners. Financial products like leases, PPAs, and loans allow qualified customers to adopt renewable energy with no money down by financing their system for up to 25 years.

07:33 EDT SunCoke Energy raises quarterly dividend to 10c from 8c per share - SunCoke Energy announced that its Board of Directors approved an increased cash dividend of 10c per share of the company's common stock, representing a 25% increase over the regular quarterly cash dividend of 8c per share. The announced dividend is payable on September 1 to stockholders of record at the close of business on August 17.

07:31 EDT Gilat Satellite, Satcom Direct sign strategic agreement to join ESA project - Satcom Direct and Gilat Satellite Networks have signed a strategic agreement to develop and supply new ultra-low profile electronically steered antennas, ESA, to support in-flight connectivity for business, government, and defense. Available from 2025 and designed for optimized compatibility with the OneWeb low earth orbit constellation, the hardware strengthens the Plane Simple Antenna Series portfolio with the addition of the Gilat advanced ESA that will unlock the full broadband potential of OneWeb. The collaboration will see Gilat develop the antenna system while Satcom Direct Avionics, the Canadian hardware manufacturing division of SD, will work with OneWeb to develop the SD Modem Unit to harness the full potential of the LEO constellation. "We are honored to have been selected by Satcom Direct to provide them with our expertise to develop this new ESA product," said Adi Sfadia, Gilat CEO. "Together, we will create a next-generation ESA to support the dynamic connectivity demands of the global business aviation sector with a best-in-class antenna. The agreement gives us the opportunity to expand our proven technology know-how in commercial aviation and to showcase our expertise alongside Satcom Direct, the only company dedicated to delivering satcom connectivity to business and government aviation worldwide. It is a major milestone for Gilat as we extend our global IFC leadership in commercial aviation to business aviation, as well as into our strategic focus area in government and defense."

07:28 EDT Bitfarms mines 378 bitcoin in July - Bitfarms provides a Bitcoin, BTC, production and mining operations update for July 2023. "We follow a disciplined and accretive growth strategy of securing low-cost power and investing capital wisely in highly efficient operations with compelling projected returns," said Geoff Morphy, CEO of Bitfarms. "To this end, in July we initiated an expansion plan to nearly double our hydropower capacity to 350 MW by acquiring 150 MW of under-utilized hydropower in Paraguay. As an industry veteran of over five years with operations in four countries, Bitfarms has a proven track record of expeditiously establishing operations in new jurisdictions. Through expansion in Paraguay, the Company seeks to leverage its industry knowledge and economies of scale to drive greater production efficiency. We plan to commence construction on the first 50 MW facility here in Q3 2023." "In July, we started production at our 11th farm in Baie-Comeau. It is on track to reach its first 11 MW of production in Q3 2023 with an additional 11 MW targeted to come online in 2H 2024. Upon completion, Baie-Comeau will increase our Quebec portfolio to 8 sites and 170 MW of low-cost hydro power. With miner deliveries and installations progressing smoothly in Rio Cuarto, Argentina, we are confident we will achieve our Q3 2023 target hashrate of 6.3 EH/s," concluded Morphy.

07:27 EDT Charge Enterprises acquires Greenspeed Energy - Charge Enterprises announced the successful acquisition of Greenspeed Energy, a provider of sustainable energy solutions including EV charging infrastructure, solar, and energy storage. The integration of Greenspeed into Charge's organization is anticipated to have a strategic impact on Charge's Infrastructure segment. By acquiring Greenspeed, Charge obtained approximately $12M in project backlog, bringing the combined backlog for the Infrastructure segment to approximately $150M as of June 30. The combined EV charging infrastructure installations will now total approximately 600 charging stations, consisting of 410 level 2 charging stations and 190 DCFC charging stations. In addition, both Greenspeed and Charge have proactively installed infrastructure to accommodate additional chargers their customers purchase in the future to meet the rising demands of EV charging. The combined skilled workforce is expected to be a customer service differentiator for Charge but is also expected to enable higher margins as more work is performed in-house. Charge looks to capitalize on the combination of Greenspeed with its existing EV charging infrastructure business to drive efficiencies, provide even better and more comprehensive customer solutions, further enhance its nationwide capabilities, and ultimately provide more value to customers and shareholders. The transaction is expected to be accretive to both EBITDA and free cash flow in the first full year of ownership.

07:26 EDT Tonix Pharmaceuticals completes enrollment in Phase 3 RESILIENT trial - Tonix Pharmaceuticals announced that it has completed enrollment of its potentially final, confirmatory Phase 3 RESILIENT trial of TNX-102 SL 5.6 mg in fibromyalgia and expects topline data next quarter. A total of 457 participants were randomized. If successful, the company believes this will be the final, well-controlled efficacy trial required for submission of a New Drug Application for approval by the U.S. Food and Drug Administration. "The completion of enrollment in our Phase 3 RESILIENT trial is a significant milestone for both Tonix and the fibromyalgia community," said Seth Lederman, M.D., Chief Executive Officer of Tonix. "Currently-approved treatments have not fully met the needs of fibromyalgia patients and there has not been a new FDA-approved therapy for the condition since 2009. TNX-102 SL has the potential to be a new non-addictive, non-opioid bedtime medication with broad spectrum symptom coverage and which can be used on a chronic basis for the management of fibromyalgia. With all other clinical, nonclinical and CMC requirements for an NDA submission achieved, we are looking forward to the upcoming data readout and an expeditious filing of an NDA."

07:25 EDT TG Therapeutics, Neuraxpharm enter ex-U.S. commercialization agreement - TG Therapeutics announced an agreement for the ex-US commercialization of BRIUMVI. BRIUMVI is the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion, twice a year, following the starting dose. Neuraxpharm is backed by funds advised by the global private equity firm, Permira. Under the terms of the commercialization agreement, TG Therapeutics will receive an upfront payment of $140 million plus an additional $12.5 million upon launch in the first EU country and is eligible to receive up to an additional $492.5 million in milestone-based payments on achievement of certain launch and commercial milestones. The total deal is valued at up to $645 million in upfront and milestone payments. In addition, TG will receive tiered double-digit royalties on net product sales up to 30%. In exchange, Neuraxpharm will have the exclusive right to commercialize BRIUMVI in territories outside the United States, Canada, and Mexico, which are retained by TG, and excluding certain Asian countries previously partnered. Additionally, TG Therapeutics retains an option to buy back all rights under the commercialization agreement for a period of two years in the event of a change in control of TG. BRIUMVI is currently approved and commercially available in the US for patients with RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI has also been approved by the European Commission for the treatment of adult patients with RMS who have active disease defined by clinical or imaging features. With this approval, the centralised marketing authorisation is valid in all EU Member States, Iceland, Norway and Liechtenstein. Approval in the United Kingdom and Switzerland will also be pursued.

07:24 EDT Bio-Path announces results from interim analysis of prexigebersen - Bio-Path reports interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with frontline therapy. The protocol for the Phase 2 study allows Bio-Path to conduct an interim efficacy analysis on each cohort at its discretion. Additional data will become available as final efficacy reviews are conducted. The primary objective of the study is to assess whether prexigebersen in combination with decitabine plus venetoclax provides higher response rates than decitabine plus venetoclax in AML patients and whether prexigebersen in combination with decitabine provides higher response rates than decitabine alone in AML patients. Efficacy data from the initial interim analysis of Cohort 1 and Cohort 2 are compelling and show that prexigebersen-based combination therapy was not only safely administered in Cohort 1 and Cohort 2 to high-risk newly diagnosed and refractory/relapsed AML patients considered unsuitable for standard chemotherapy, but also demonstrated efficacy signals significantly better than current therapies. As a result of the interim review, Bio-Path has demonstrated superiority of prexigebersen combination therapy in treating AML patients and currently plans to pursue U.S. Food and Drug Administration expedited programs for Fast Track and Breakthrough Therapy designations.

07:23 EDT Rio Tinto, Azimut sign two 'option to joint venture agreements' - Victory Battery Metals shares that Rio Tinto Exploration Canada Inc. has just signed "two Option to Joint Venture Agreements" with Azimut Exploration for Azimut's Kaanaayaa and Corvet lithium properties, situated directly to the east and south of Victory's Lac Block and Riviere Block, for up to C$115.7M. Victory CEO and Director, Mr. Mark Ireton commented: "The Rio Tinto Exploration / Azimut Exploration options to joint venture represent a significant advance in the direct area of Victory's Stingray claims. Our exploration team is finalizing a comprehensive phase one work program for Stingray, the details for which we will be able to announce in short order. We are highly encouraged by Patriot Battery Metals announcement of the largest Lithium Pegmatite Resource in the Americas on 30 July 2023 for its Corvette Property, directly to the north of Victory's Stingray array of properties - and pleased that Canada, in particular Quebec, is being recognized globally as a major player in the EV revolution, specifically in this prolific area in which we have substantial and well-placed ground."

07:21 EDT Entrada receives authorization in the UK for Phase I trial of ENTR-601-44 - Entrada Therapeutics announced that it has received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44. ENTR-601-44 is Entrada's lead product candidate within its Duchenne franchise and is being developed for the potential treatment of individuals with Duchenne who are exon 44 skipping amenable. The Phase 1 trial's primary objective is to evaluate the safety of a single dose of ENTR-601-44 in healthy volunteers, with a target enrollment of approximately 40 participants. The trial will also evaluate tolerability, pharmacokinetics and target engagement as measured by exon skipping in the skeletal muscle. The first participant is expected to be dosed in September of this year with data anticipated in the second half of 2024.

07:20 EDT Incyte chief scientific officer Dashyant Dhanak to leave organization - Dashyant Dhanak, who has served as Incyte's chief scientific officer since 2018, will be leaving the organization effective August 2 in order to pursue other interests. Under his leadership, Incyte has filed more than fifteen Investigational new drug applications, and has made advancements in the biotherapeutics and small molecule pipeline.

07:19 EDT TG Therapeutics expects cash to fund operations for 'foreseeable future' - Cash, cash equivalents and investment securities were $144.9 million as of June 30, 2023. We anticipate that our cash, cash equivalents and investment securities as of June 30, 2023, combined with the upfront payment of $140.0 million received as part of our ex-U.S. commercialization agreement and projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will be sufficient to fund our planned operations for the foreseeable future.

07:16 EDT Neurocrine raises 2023 net product sales view to $1.77B-$1.82B - Consensus for 2023 total revenue is $1.83B.

07:15 EDT RedHill Biopharma: Talicia approved in the United Arab Emirates - RedHill Biopharma announced that its partner, Gaelan Medical, a wholly owned subsidiary of the Ghassan Aboud Group, has received marketing approval from the United Arab Emirates Ministry of Health for Talicia. The approval makes Talicia the first approved rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori.

07:14 EDT Rhythm Pharmaceuticals expects cash to fund operations into 2025 - For the year ending December 31, 2023, Rhythm continues to anticipate approximately $200 million to $220 million in Non-GAAP Operating Expenses, comprised of $120 million to $130 million from R&D expenses and $80 million to $90 million from S,G&A expenses. Based on its current operating plans, Rhythm expects that its existing cash, cash equivalents and short-term investments as of June 30, 2023, together with the anticipated $25 million milestone payment based on commercial sales from Healthcare Royalty Partners, will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.

07:12 EDT Sirius XM CFO says expect to see improving performance in second half - SiriusXM's Chief Financial Officer Thomas Barry stated: "Our solid second quarter performance and greater visibility into full-year cash taxes and working capital leads us to increase our 2023 free cash flow outlook to $1.15 billion. We also expect to continue to see improving financial and operating performance in the second half of the year. Our team continues to focus on cost levers and operational efficiencies while reinvesting savings in enhanced technology, including our consumer app set to launch in the fall and an all-new commerce and identity platform."

07:10 EDT Marriott reports Q2 comparable systemwide constant dollar RevPAR up 13.5% - Q2 comparable systemwide constant dollar RevPAR increased 13.5% worldwide, 6% in the U.S. & Canada, and 39.1% in international markets, compared to the 2022 second quarter. The company added approximately 33,100 rooms globally during the second quarter, including 17,300 rooms associated with the City Express transaction and roughly 11,200 other rooms in international markets. Marriott also added more than 2,800 conversion rooms. At the end of the quarter, Marriott's worldwide development pipeline totaled more than 3,100 properties and nearly 547,000 rooms, including roughly 31,500 of pipeline rooms approved, but not yet subject to signed contracts. More than 240,000 rooms in the pipeline, including approximately 37,000 rooms from the company's deal with MGM Resorts International, were under construction as of the end of the second quarter.

07:04 EDT Revolution Medicines to acquire EQRx in all-stock transaction - Revolution Medicines (RVMD) and EQRx (EQRX) announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines' balance sheet. The total number of shares of Revolution Medicines common stock to be issued to EQRx security holders will be determined in close proximity to the closing of the stockholder votes on the transaction. The deal, which was overseen by independent committees of Revolution Medicines' and EQRx's respective boards of directors, has been approved by the directors of each company. The transaction, which is subject to customary closing conditions, will enhance Revolution Medicines' efforts to fulfill its vision to discover, develop and deliver pioneering RAS(ON) Inhibitor drugs on behalf of patients with RAS-addicted cancers. This proposed transaction is intended to reinforce and sustain Revolution Medicines' parallel development approach for its extensive RAS(ON) Inhibitor pipeline in multiple RAS-driven cancers by enhancing its balance sheet, increasing financial certainty in a challenging macroenvironment. With encouraging data trends thus far for its RASMULTI(ON) Inhibitor RMC-6236, planning is underway for one or more single agent pivotal clinical trials potentially to begin in 2024. Likewise, with encouraging initial clinical experience with its KRASG12C(ON) Inhibitor RMC-6291, planning is underway for a Phase 1/1b clinical trial to evaluate the combination of RMC-6236 and RMC-6291 potentially to begin in early 2024, while continuing single agent evaluation of RMC-6291. Revolution Medicines' acquisition of EQRx reflects both companies' confidence in Revolution Medicines' ability to deploy this amount of capital effectively. With the additional capital, Revolution Medicines will be positioned to maximize the potential clinical impact of its targeted drug pipeline across multiple oncology indications, and thereby offers the potential for shareholder value creation while retaining strategic control of its RAS(ON) Inhibitor pipeline. Under the terms of the merger agreement, Revolution Medicines will acquire EQRx in an all-stock transaction. The stock exchange ratio formula in the merger agreement uses a blended average to account for developments in Revolution Medicines' ongoing business and potential movement in its stock price. Approximately 80% of the stock exchange ratio is based on Revolution Medicines' public market stock price measured in close proximity to the EQRx stockholder vote and the remaining 20% of the exchange ratio is a determined price per share of Revolution Medicines' stock as of the signing of the merger agreement. Specifically, at closing, EQRx stockholders will receive the number of shares of Revolution Medicines common stock equal to the sum of 7,692,308 Revolution Medicines shares plus a number of shares equal to $870 million divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines share price measured in close proximity to the stockholder vote. Certain EQRx stockholders, representing more than 40% of voting shares of EQRx, have entered into support and voting agreements to vote their shares in favor of the transaction. At the close of the transaction, one EQRx director will be designated by Revolution Medicines to serve on its board of directors. The transaction is expected to close in November 2023, subject to satisfaction of customary closing conditions, including regulatory review, and approval by Revolution Medicines' and EQRx's stockholders. Upon completion of the transaction, EQRx shares will cease trading on the Nasdaq Global Market. Revolution Medicines announces that an update on the clinical antitumor activity of RMC-6236 in patients with non-small cell lung cancer or pancreatic cancer will be presented as a Proffered Paper during the Developmental Therapeutics session on Sunday, October 22 at the 2023 European Society for Medical Oncology Congress, and supporting clinical data will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October. Revolution Medicines is an invited speaker in a plenary session at the Triple Meeting delivering a presentation entitled "Targeting RAS-addicted Cancers with Investigational RAS(ON) Inhibitors". Furthermore, a first report on initial clinical findings with RMC-6291, including preliminary evidence of differentiation from RAS(OFF) inhibitors, will be presented at the Triple Meeting. Additional details on the above presentations will be provided when available. The company also announces that study site activation is ongoing under an investigational new drug application for a Phase 1/1b trial of RMC-9805. To maximize the likelihood of success and the breadth of potential impact for Revolution Medicines' most promising R&D assets, the company has made the strategic decision to concentrate its post-merger financial and human capital on its three priority RAS-focused assets, as well as its deep pipeline of mutant-selective RAS(ON) Inhibitors. In line with Revolution Medicines' continued prioritization and focus of its resources on novel drug mechanisms of action targeting RAS-addicted cancers, Revolution Medicines does not intend to advance EQRx's research and development portfolio following closing of the transaction. EQRx will commence a process to wind down these programs and return the associated intellectual property to its partners, which would have the opportunity to independently decide the next steps on development.

07:02 EDT Uber to evaluate returning excess capital to shareholders - In prepared remarks following its Q2 earnings report, Uber CEO Dara Khosrowshahi said the company will evaluate returning excess capital to shareholders. The CEO said Uber Freight continued to be pressured by category-wide headwinds with industry spot rates seasonally weak, "a trend we expect to continue in the near term." Uber expects Trips to grow at least 20% in Q3 y/y.

06:58 EDT Uber sees Q3 gross bookings $34B-$35B, adjusted EBITDA $975M-$1.025B

06:57 EDT Uber CEO: Robust demand resulted in 'excellent' quarter - "Robust demand, new growth initiatives, and continued cost discipline resulted in an excellent quarter, with trips up 22% and a GAAP operating profit, for the first time in Uber's history," said Dara Khosrowshahi, CEO. "These results also translated into strong driver and courier engagement, with 6 million drivers and couriers earning a record $15.1 billion during the quarter."

06:49 EDT Pfizer CEO says 'significant progress' toward goal of launching 19 new products - Dr. Albert Bourla, Chairman and CEO, stated: "Pfizer has made significant progress toward our goal to launch 19 new products and indications in an 18-month span, having executed eleven launches thus far. We continue to build momentum in 2023, recently attaining key milestones for several products, including the U.S. launches of Prevnar 20 in pediatric patients and Zavzpret; U.S. approvals and launches for Abrysvo in older adults, Litfulo and the Talzenna plus Xtandi combination; U.S. approvals for Ngenla (expected to be available for prescribing this month) and Paxlovid; and U.S. regulatory filing acceptance for fidanacogene elaparvovec (Hemophilia B Gene Therapy). Supporting our expectation to deliver robust operational growth in 2025 and beyond, we also reported data from several exciting pipeline candidates we believe have the potential to be significant future value-drivers, including Phase 3 data from marstacimab, Pfizer's novel, investigational anti-TFPI antibody being studied for the treatment of hemophilia A or B; further data from elranatamab, Pfizer's investigational BCMA CD3-targeted bispecific antibody currently being investigated in multiple myeloma; and first-in-human data from our pipeline of potential next-generation breast cancer treatments, including our novel CDK4, CDK2, and KAT6 inhibitors. Finally, we continue to make progress toward our proposed acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative oncology medicines. In addition to receiving approval of the transaction from Seagen shareholders and planning for the potential integration of the two companies, we continue to work closely with regulators, including the Federal Trade Commission and the European Commission, and are working diligently to fulfill requests for further information from the FTC. We look forward to continuing our progress in the second half of 2023, driven by commercial execution, scientific innovation and our never-ending commitment to delivering breakthroughs for patients."

06:41 EDT Graphic Packaging announces $500M increase to share repurchase program - The company said, "Consistent with that, we are pleased to announce a definitive agreement to acquire Bell Incorporated, a well-capitalized U.S. packaging provider, strategically expanding our network, customer breadth and category presence. The pending transaction will strengthen our integrated packaging network in the U.S., further solidifying our commitment to deliver service excellence in packaging. Our Board of Directors has also approved an incremental $500 million share repurchase authorization. These announcements demonstrate our balanced approach to capital allocation as we continue to deliver value for stakeholders."

06:41 EDT BP sees 2023 reported upstream production higher vs. 2022 - bp now expects both reported and underlying upstream production to be higher compared with 2022. Within this, bp expects underlying production from oil production & operations to be higher and production from gas & low carbon energy to be slightly lower. bp now expects four major project start-ups during 2023, with Greater Tortue Ahmeyim Phase 1 now expected to start-up during the first quarter of 2024. bp continues to expect the other businesses & corporate underlying annual charge to be in a range of $1.1-1.3 billion for 2023. The charge may vary from quarter to quarter. bp continues to expect the depreciation, depletion and amortization to be slightly above 2022. bp continues to expect the underlying ETR for 2023 to be around 40% but it is sensitive to the impact that volatility in the current price environment may have on the geographical mix of the group's profits and losses. Having realized $16.8 billion of divestment and other proceeds since the second quarter of 2020, bp continues to expect divestment and other proceeds of $2-3 billion in 2023 and continues to expect to reach $25 billion of divestment and other proceeds between the second half of 2020 and 2025. bp continues to expect Gulf of Mexico oil spill payments for the year to be around $1.3 billion pre-tax including the $1.2 billion pre-tax payment made during the second quarter. bp continues to expect capital expenditure of $16-18 billion in 2023 including inorganic capital expenditure. bp is committed to maintaining a strong investment grade credit rating, targeting further progress within an 'A' grade credit rating. For 2023 bp continues to intend to allocate 40% of surplus cash flow* to further strengthening the balance sheet. For 2023 and subject to maintaining a strong investment grade credit rating, bp remains committed to using 60% of surplus cash flow for share buybacks. In setting the dividend per ordinary share and buyback each quarter, the board will continue to take into account factors including the cumulative level of and outlook for surplus cash flow, the cash balance point* and the maintenance of a strong investment grade credit rating. Based on bp's current forecasts, at around $60 per barrel Brent and subject to the board's discretion each quarter, bp continues to expect to be able to deliver share buybacks of around $4.0 billion per annum, at the lower end of its $14-18 billion capital expenditure range, and have capacity for an annual increase in the dividend per ordinary share of around 4%

06:38 EDT BP sees Q3 oil prices 'supported' by seasonal demand, OPEC restrictions - For the third quarter, bp expects oil prices to be supported by seasonal demand and the OPEC+ production restrictions. During the third quarter, bp expects the risk of an earlier than normal seasonal fill of European gas storage to continue to weigh on European gas and Asian LNG prices absent disruptions to supply. In the US, Henry Hub gas prices are expected to find support from coal-to-gas switching in the power sector. In the third quarter, bp expects industry refining margins to remain above historical average levels, supported by low product inventories and seasonal demand in the US

06:32 EDT BP intends to execute further $1.5B share buyback - "In the second quarter bp has continued to execute against its unchanged financial frame. We have increased our dividend by 10%; we are investing with discipline to advance our strategy; and we are committed to returning 60% of 2023 surplus cash flow through share buybacks with a further $1.5 billion announced for the second quarter," said Murray Auchincloss, CFO.

06:25 EDT Hercules Capital raises Q2 total cash distribution to 48c per share - Hercules Capital has increased and declared a Q2 total cash distribution of 48c per share. The record date is August 18 and the payment date is August 25. Of the distributions declared during the quarter ended June 30, 2023, 100% were distributions derived from the company's current and accumulated earnings and profits. The percentage of QII for distributions declared for Q2 on Hercules' common stock is 87.39%.

06:23 EDT Li-Cycle starts operations at first Spoke recycling facility in Europe - Li-Cycle Holdings is pleased to announce the start of commercial operations at its first Spoke recycling facility in Europe, located in Magdeburg, Germany. The Germany Spoke's first main processing line has now commenced operations, with the second main line expected to start later in 2023. Each main line has the capacity to process up to 10,000 tonnes of lithium-ion battery material per year. With an additional 10,000 tonnes of ancillary capacity planned, the facility is expected to have a total capacity of 30,000 tonnes per year, making the Germany Spoke the largest Spoke in Li-Cycle's current portfolio and one of the largest facilities of its kind on the continent.

06:15 EDT Crestwood Equity still sees 2023 Adjusted EBITDA $780M-$860M

06:02 EDT Hims & Hers announced expansion into cardiovascular health - Hims & Hers Health announced yesterday afternoon an expansion into cardiovascular health. Through Heart Health by Hims, "providers will be able to personalize treatments to combine active ingredients found in clinically proven medications to address multiple conditions in one pill, demonstrating Hims & Hers' rapidly advancing technology and pharmacy capabilities," the company said in a statement. Hims & Hers also announced a strategic collaboration with the American College of Cardiology. The Heart Health by Hims approach uses clinical protocols that are based on principles of the ACC's Atherosclerotic Cardiovascular Disease risk estimator. In addition, Heart Health by Hims customers will have access to cardiovascular health resources and education materials through CardioSmart.org, the patient engagement initiative of the ACC, the company said.

05:32 EDT Nio delivers 20,462 vehicles in July - Nio announced its July delivery results. Nio delivered 20,462 vehicles in July, representing an increase of 103.6% year-over-year. The deliveries consisted of 14,066 premium smart electric SUVs, and 6,396 premium smart electric sedans. Cumulative deliveries of NIO vehicles reached 364,579 as of July 31. The deliveries of the All-New ES6, a smart electric all-round SUV, have been growing solidly since its debut in late May and exceeded 10,000 units monthly in July. The All-New ES6 caters to wide-ranging journeys of users for their family, business and leisure needs. In July, both ET5 and EL7 were awarded the five-star rating in 2023 Euro NCAP safety tests. Both models achieved the best Euro NCAP scores since 2020 for sedans and SUVs respectively in the vehicle crash tests for occupant protection.

05:27 EDT Faraday Future launches second phase of co-creation delivery - Faraday Future announced the official launch of the second phase of its co-creation delivery, and will deliver the FF 91 2.0 Futurist Alliance to the first users. This marks a significant milestone for the company as FF initiates the second phase of its three-phase delivery plan. FF has also successfully completed all compliance testing of the FF 91 2.0 Futurist Alliance. FF remains committed to safety and the FF 91 2.0 Futurist Alliance vehicles meet the standards, providing users with top-notch safety features. The first co-creation delivery process of the FF 91 2.0 Futurist Alliance will begin in the second week of August. A delivery ceremony is planned to be held in the middle of August to honor and celebrate this momentous occasion with the first user. As FF begins the delivery process to its initial users, the company simultaneously launches the selection and signing process for the second group of users that will also join the company's developer co-creation project. This exciting opportunity opens the doors for more potential users to become part of the FF 91 2.0 Futurist Alliance experience. The company plans to recruit co-creation participants on the basis of a recommendation and invitation system along with the launch of the second phase of developer co-creation delivery. Potential developer co-creators must receive at least one recommendation from an existing FF developer co-creator or an FF pre-order holder. Furthermore, only those who pass the company's evaluation will have the opportunity to become developer co-creators and subsequently qualify as vehicle owners in the second phase of developer co-creation. The company has now initiated the selection process for developer co-creators participating in the first Developer Co-creation Festival at Pebble Beach, California during Monterey Car Week.

05:11 EDT Mainz Biomed launches ColoAlert with Marylebone Laboratory in the UK - Mainz Biomed announced that London-based Marylebone Laboratory has introduced ColoAlert, Mainz Biomed's flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer, or CRC, to its extensive UK and international customer base.

05:05 EDT XPeng delivers 11,008 Smart EVs in July - XPeng announced its vehicle delivery results for July. In July, Xpeng recorded monthly deliveries of 11,008 Smart EVs, a 28% increase over the prior month, marking its sixth consecutive month of delivery growth. XPeng's G6 Ultra Smart Coupe SUV commenced mass deliveries across 110 cities nationwide in July after its market launch in late June. In July, total G6 deliveries reached more than 3,900 units. The strong sales momentum of G6 has led to a surge in showroom visits, which, in turn, has increased customers' enthusiasm for other XPeng Smart EV models and the advanced smart technology equipped within. The company is focused on ramping up the G6's production with its manufacturing facilities running at its full load. The company also increased dedicated logistics resources to ensure the speed of G6 deliveries.